Mark Storey: From asymptomatic to oligo, we remain a critical component of treatment

Mark Storey, Radiation Oncologist at the Oklahoma Proton Center, shared on X/Twitter:

“Today’s article looks at radiation in the metastatic setting – Four trials from 2023. Two with OS benefit (while SABR-COMET sits in backdrop). From asymptomatic to oligo, we remain a critical component of treatment.”